

Leela Palaces Hotels & Resorts

India | Hotels | Result Update



18 January 2026

Asset-led growth to start from FY28

Leela Palaces, Hotels and Resorts (THELEELA IN) reported good, though in-line results, driven by a 160bp improvement in occupancy to 71% and 18% average room rate (ARR) growth to INR 30,337. Occupancy and ARR grew across businesses, up 400bp & 28%, respectively, and the leisure portfolio was up 100bp and 17%, respectively. THELEELA has made provision of INR 64mn on account of recent changes in the Labour Law. The *Leela Palace Jaipur* has been undergoing a comprehensive upgrade to be repositioned as a sought-after leisure travel destination for foreign as well as domestic travellers. THELEELA plans to start renovation of the Dubai hotel in FY28 and open the hotel after rebranding in FY29. The benefits accruing would be back-ended but significant. Work on building the remaining 762 keys is continuing as per plan. THELEELA is a play on increasing number of high net worth individuals (HNI) seeking luxury experiential travel. HNI count in India is growing in the double digits pa but huge entry barrier is constraining supply of ultra luxury hotels, which is poised to benefit incumbent luxury hoteliers. We retain **Buy** with a higher TP of INR 620 based on 22x 9MFY28E EV/EBITDA as we roll forward our valuation to 9MFY28E financials.

Materials revenue contribution from Dubai from FY29: THELEELA closed the Dubai hotel acquisition on 26 November 2025, buying a 25% equity stake along with securing hotel management agreement. The total equity commitment, including future capex, is INR 6.4bn, of which ~INR 4.0bn has been deployed to date. Sofitel will continue to manage the hotel during the transition period. Renovation and upgrade activities are scheduled to commence in FY28, followed by rebranding to *Leela Palace* in FY29 before reopening. Consequently, significant management fee income and earnings contribution from the hotel are from FY29. Given the renovation timeline, principal value accretion from the hotel asset is back-ended, positioning Dubai as a long-term, capital-efficient growth lever rather than a near-term earnings driver. Equity invested in the Dubai hotel is likely to be recovered by FY30 through the sale of branded residences, materially reducing net capital employed for the hotel by THELEELA. This is set to render the hotel business effectively asset-light in the medium term despite having a 25% stake in the profit pool.

Retain Buy with a higher TP of INR 620: THELEELA's structural growth would be driven by asset-led expansion from FY28 while the Dubai hotel acquisition would start to materially reflect in financials from FY29. We increase our EBITDA and PAT estimates by 8% and 17% for FY26 and by 4% and 15% for FY27, respectively. We retain **Buy** with a higher TP of INR 620 from INR 569 based on 22x Q3FY28E EV/EBITDA as we roll forward our valuation to 9MFY28E financials.

Rating: **Buy**

Target Price: **INR 620**

Upside: **41%**

CMP: **INR 441**


As on 16 January 2026

Key data

Bloomberg	THELEELA IN
Reuters Code	SCHLNS
Shares outstanding (mn)	334
Market cap (INR bn/USD mn)	147/1,621
EV (INR bn/USD mn)	154/1,698
ADTV 3M (INR mn/USD mn)	162/2
52 week high/low	475/381
Free float (%)	24

Note: as on 16 January 2026; Source: Bloomberg

Price chart



Source: Bloomberg

	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Shareholding (%)				
Promoter	0.0	0.0	75.9	75.9
% Pledge	0.0	0.0	0.0	0.0
FII	0.0	0.0	8.6	8.5
DII	0.0	0.0	8.2	11.1
Others	0.0	0.0	7.3	4.5

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(0.1)	2.9	10.7
Leela Palaces Hotels &	(0.1)	(2.3)	0.0
NSE Mid-cap	0.4	1.5	9.4
NSE Small-cap	(5.1)	(9.5)	(3.0)

Source: Bloomberg

Key financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	11,715	13,006	15,374	17,303	21,678
YoY (%)	36.2	11.0	18.2	12.5	25.3
EBITDA (INR mn)	5,450	5,944	7,427	8,082	10,315
EBITDA margin (%)	46.5	45.7	48.3	46.7	47.6
Adj PAT (INR mn)	(21)	477	3,926	4,947	5,877
YoY (%)	(96.6)	(2,340.6)	723.7	26.0	18.8
Fully DEPS (INR)	(1.1)	1.7	11.8	14.8	17.6
RoE (%)	0.1	12.2	7.8	7.3	8.1
RoCE (%)	30.5	10.2	7.9	8.3	9.9
P/E (x)	(418.3)	255.9	37.5	29.8	25.1
EV/EBITDA (x)	28.3	26.0	20.8	19.1	15.0

Note: Pricing as on 16 January 2026; Source: Company, Elara Securities Estimate

Prashant Biyani

Fertilizers & Agricultural Chemicals,
Hotels, Sugar
+91 22 6164 8581
prashant.biyani@elaracapital.com

Associate
Yashi Jain
yashi.jain@elaracapital.com



Financials (YE March)

Income Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Total Revenue	11,715	13,006	15,374	17,303	21,678
Gross Profit	10,865	12,058	14,307	16,058	20,179
EBITDA	5,450	5,944	7,427	8,082	10,315
EBIT	3,970	4,544	6,227	6,846	8,686
Interest expense	4,326	4,582	2,033	1,403	1,335
Other income	550	1,060	791	538	535
Exceptional/ Extra-ordinary items	-	-	(64)	-	-
PBT	194	1,023	4,921	5,981	7,886
Tax	216	544	984	1,196	1,577
Minority interest/Associates income	-	(2)	(75)	162	(431)
Reported PAT	(21)	477	3,862	4,947	5,877
Adjusted PAT	(21)	477	3,926	4,947	5,877
Balance Sheet (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Shareholders' Equity	(28,257)	35,569	64,507	69,292	75,600
Minority Interest	-	481	481	481	481
Trade Payables	599	607	758	853	1,069
Provisions & Other Current Liabilities	51,052	1,419	1,599	1,800	2,255
Total Borrowings	42,422	39,087	17,087	14,087	15,587
Other long term liabilities	4,803	5,499	5,933	6,295	7,118
Total liabilities & equity	70,619	82,662	90,365	92,808	102,110
Net Fixed Assets	55,475	57,267	63,385	64,663	70,605
Goodwill	4,671	4,671	4,671	4,671	4,671
Intangible assets	676	445	445	445	445
Business Investments / other NC assets	3,334	3,804	10,599	11,823	15,486
Cash, Bank Balances & treasury investments	4,882	13,943	8,720	8,329	7,287
Inventories	310	272	421	474	594
Sundry Debtors	729	887	1,053	1,185	1,485
Other Current Assets	543	1,374	1,070	1,218	1,537
Total Assets	70,619	82,662	90,365	92,808	102,110
Cash Flow Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Cashflow from Operations	5,388	5,530	7,489	7,387	9,205
Capital expenditure	(1,199)	(2,076)	(7,318)	(2,514)	(7,572)
Acquisitions / divestitures	(4,246)	(46,894)	-	-	-
Other Business cashflow	(2,416)	(8,185)	-	-	-
Free Cash Flow	(2,472)	(51,624)	171	4,873	1,633
Cashflow from Financing	1,470	52,359	1,401	(4,040)	987
Net Change in Cash / treasury investments	1,845	9,062	(5,223)	(392)	(1,042)
Key assumptions & Ratios	FY24	FY25	FY26E	FY27E	FY28E
Dividend per share (INR)	-	-	-	-	-
Book value per share (INR)	(1,401.0)	128.6	193.2	207.5	226.4
RoCE (Pre-tax) (%)	30.5	10.2	7.9	8.3	9.9
ROIC (Pre-tax) (%)	43.9	12.9	9.3	9.2	10.9
ROE (%)	0.1	12.2	7.8	7.3	8.1
Asset Turnover (x)	0.2	0.2	0.3	0.3	0.3
Net Debt to Equity (x)	(1.3)	0.7	0.1	0.1	0.1
Net Debt to EBITDA (x)	6.9	4.2	1.1	0.7	0.8
Interest cover (x) (EBITDA/ int exp)	1.3	1.3	3.7	5.8	7.7
Total Working capital days (WC/rev)	(1,623.8)	426.7	229.1	191.1	141.9
Valuation	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	(418.3)	255.9	37.5	29.8	25.1
P/Sales (x)	12.6	11.3	9.6	8.5	6.8
EV/ EBITDA (x)	28.3	26.0	20.8	19.1	15.0
EV/ OCF (x)	28.6	27.9	20.6	20.9	16.8
FCF Yield	(1.6)	(33.5)	0.1	3.2	1.1
Price to BV (x)	(0.3)	3.4	2.3	2.1	1.9
Dividend yield (%)	-	-	-	-	-

Note: Pricing as on 16 January 2026; Source: Company, Elara Securities Estimate

Exhibit 1: Quarterly financials

Consolidated financials (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Variance (%)	9MFY26	9MFY25	YoY (%)
Cons Net Sales	4,574	3,705	23.5	3,106	47.3	4,704	(2.8)	10,429	8,850	17.8
Food & Beverages consumed	312	256	21.7	240	29.9	375	(17.0)	748	674	10.9
Employee cost	784	685	14.5	727	7.8	894	(12.3)	2,241	1,999	12.1
Other Expenses	1,100	895	22.9	760	44.8	1,082	1.7	2,668	2,408	10.8
Total Expenditure	3,474	2,810	23.6	2,347	48.1	2,351	47.8	7,761	6,443	20.5
EBITDA	2,378	1,869	27.2	1,379	72.4	2,353	1.1	4,772	3,769	26.6
Margin (%)	52.0	50.4	155bp	44.4	759bp	50.0	197bp	45.8	42.6	317bp
Depreciation	294	315	(6.7)	270	8.9	315	(6.7)	828	1,089	(24.0)
EBIT	2,084	1,554	34.1	1,109	87.9	2,038	2.3	3,944	2,680	47.2
Interest	394	1,172	(66.3)	381	3.6	400	(1.4)	1,635	3,589	(54.4)
Other Income	134	330	(59.3)	228	(41.1)	250	(46.3)	628	678	(7.5)
Exceptional Items	(64)	-	NA	-	NA	-	NA	(64)	-	NA
PBT	1,760	712	147.2	957	(84.6)	1,888	(6.8)	2,873	(230)	(1,346.6)
Tax	256	147	74.7	185	38.4	483	(46.9)	512	372	37.5
Tax Rate (%)	5.6	4.0	164bp	6.0	(35.8)	25.60	(1,999)bp	17.81	(161.5)	17,929bp
RPAT	1,479	564	162.0	747	97.9	1,379	7.2	2,313	(606)	(481.9)
APAT	1,543	564	173.5	748	106.4	1,379	11.9	2,379	(606)	(492.7)
Adj EPS (INR)	4.6	0.6	620.5	2.2	106.4	4.1	11.9	7.1	(5)	(255.0)

Source: Company, Elara Securities Estimate

Leela Palace, Jaipur's repositioning poised to drive growth

During Q3FY26, THELEELA undertook a comprehensive repositioning of *Leela Palace Jaipur* to strengthen its appeal to foreign travellers and domestic guests. The company upgraded its F&B portfolio with the launch of Aravalli Dining Room, *Jamavar* (specialty restaurant), *Peacock Lounge*, and *Amber Terrace* (rooftop bar). The *Aujasya* Spa commenced operations in Q3FY26. Optimization of under-utilized spaces improved asset productivity and guest experience, driving 27% YoY growth in Jaipur RevPAR in Q3FY26. Further enhancements, including premium villas for multi-generational travel, a children's club and gym, are scheduled to open in Q4FY26. The repositioning strengthens *Leela Palace Jaipur* to grow RevPAR, profitability, and support brand leadership against upcoming new luxury hotel supplies in the Pink City.

Managed pipeline to be operational in FY27

Three hotels, totalling to 283 keys, under management contract are likely to commence operations in FY27, including the recently acquired 80-key luxury hotel in Jaisalmer. The hotel is spread across 30 acres, undergoing upgrades to align with THELEELA's luxury standards. The addition strengthens the Rajasthan circuit across Jaipur, Udaipur, Ranthambore, and Jaisalmer, enabling cross-selling opportunities.

Exhibit 2: Room revenue contributes ~53% to Q3FY65 revenue

(INR mn)	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Room income	1,103	1,307	2,009	2,381	1,312	1,470	2,415
As a % of Revenue	48.3	45.7	54.2	56.1	47.7	47.3	52.8
F&B	914	1,136	1,288	1,444	1,063	1,206	1,662
As a % of Revenue	40.0	39.7	34.8	34.0	38.7	38.8	36.3
Management and other operating fees	117	151	204	226	141	163	219
As a % of Revenue	5.1	5.3	5.5	5.3	5.1	5.2	4.8
Others	148	334	273	-29	232	267	278
Total Revenue from operations	2282	2928	3774	4022	2748	3106	4574

Source: Company, Elara Securities Research

Exhibit 3: RevPar grows 20%, led by 18% ARR growth

(INR)	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Keys					1,224	1,224	1,224
ARR	16,698	18,042	25,827	27,918	18,817	19,290	30,337
YoY Growth (%)	3.4	(5.2)	11.2	15.7	12.7	6.9	17.5
Occupancy	60	65	69	78	64	69	71
Expansion/ (Contraction) in Occupancy (bps)	100	290	30	(40)	390	410	160
RevPar	9,975	11,712	17,912	21,678	11,963	13,262	21,551
YoY Growth (%)	5.28	(0.66)	11.59	15.26	19.93	13.23	20.32

Source: Company, Elara Securities Research

Exhibit 4: City hotels and resort hotels RevPAR grows 17% and 28%, respectively

(INR)	Q3FY26	Q3FY25	YoY (%)
City Hotels RevPar	18,553	15,905	16.6
Resort Hotels RevPar	31,499	24,560	28.3

Source: Company, Elara Securities Research

Exhibit 5: Around 1,008 keys inventory addition by FY30

Hotel	Keys	Type	Timeline
Srinagar	170	Owned	FY28
Agra	99	Owned	FY28
Ranthambore	76	Owned	FY28
Bandhavgarh	30	Owned	FY28
Ayodhya	100	Owned	FY28
Mumbai BKC	250	Owned	FY30
Sikkim	140	Managed	FY27
Mumbai Waterstone	63	Managed	FY27
Jaisalmer	80	Managed	FY27
Total keys in Pipeline	1,008		

Source: Company, Elara Securities Research

Exhibit 6: Valuation

Particulars (INR mn)	9MFY28
EBITDA	9,757
EV/EBITDA (x)	22
EV	214,654
Net Debt	7,665
Target Mcap	206,989
Outstanding shares (mn)	334
CMP (INR)	441
Target Price (INR)	620
Upside (%)	37


Note: pricing as on 16 January 2026; Source: Elara Securities Estimate

Exhibit 7: Changes in estimates

(INR mn)	Old			New			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Net Sales	15,469	17,383	22,205	15,374	17,303	21,678	(0.6)	(0.5)	(2.4)
EBITDA	6,862	7,754	10,335	7,427	8,082	10,315	8.2	4.2	(0.2)
EBITDA Margin (%)	44.4	44.6	46.5	48.3	46.7	47.6	395bp	210bp	104bp
Adjusted PAT	3,344	4,315	7,634	3,926	4,947	5,877	17.4	14.6	(23.0)
EPS (INR)	10.0	12.9	22.9	11.8	14.8	17.6	17.4	14.6	(23.0)
Target Price (INR)			569			620			8.9

Source: Elara Securities Estimate

Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
12-Aug-2025	Buy	553	432
14-Oct-2025	Buy	569	439
16-Jan-2026	Buy	620	441

Guide to Research Rating

BUY (B)	Absolute Return >+20%
ACCUMULATE (A)	Absolute Return +5% to +20%
REDUCE (R)	Absolute Return -5% to +5%
SELL (S)	Absolute Return < -5%

Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

Rule 15a6 Disclosure: This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act")) may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

Disclosures on Subject Companies: Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/and> Investors are strongly encouraged to review this information before investing.

Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("Foreign Counterparty") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("Report") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

Analyst Certification: In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Avior Capital Markets US, LLC is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

Avior Capital Markets International Limited is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

Elara Securities (India) Private Limited is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India

India
Elara Securities (India) Private Limited
 One International Center, Tower 3,
 21st Floor, Senapati Bapat Marg,
 Elphinstone Road (West)
 Mumbai – 400 013, India
 Tel : +91 22 6164 8500

Europe
Elara Capital Plc.
 6th Floor, The Grove,
 248A Marylebone Road,
 London, NW1 6JZ,
 United Kingdom
 Tel : +44 20 7486 9733

USA
Elara Securities Inc.
 230 Park Avenue, Suite 2415,
 New York, NY 10169, USA
 Tel: +1 212 430 5870
 Fax: +1 212 208 2501

Asia / Pacific
Elara Capital (Asia) Pte.Ltd.
 One Marina Boulevard,
 Level 20,
 Singapore 018989
 Tel : +65 6978 4047



**Managing
Director**

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



**Head of
Research**

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543
Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558
Himani Sanghavi - himani.sanghavi@elaracapital.com - +91 22 6164 8586



**India, APAC &
Australia**

Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508
Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541
Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567
Suyash Maheshwari - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



**Corporate
Access,
Conference &
Events**

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520
Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#).

Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500
 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933
 Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236
 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018
 Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509
 Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509